NCT07210411 Acute and Chronic Repercussion of Spinal Cord Stimulation After Spinal Cord Injury
| NCT ID | NCT07210411 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Mayo Clinic |
| Condition | Spinal Cord Injuries |
| Study Type | INTERVENTIONAL |
| Enrollment | 80 participants |
| Start Date | 2026-03-05 |
| Primary Completion | 2030-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 80 participants in total. It began in 2026-03-05 with a primary completion date of 2030-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this research is to learn about how the participant's body is able to balance changes in blood pressure, and how spinal cord stimulation affects these changes as well as immune \& cardiovascular function in participants with spinal cord injury.
Eligibility Criteria
Inclusion criteria * Age 18-50. * American Spinal Injury Association Impairment Scale A-D,64 to encompass a representational spectrum of autonomic dysfunction after spinal cord injury. * Neurological level of injury, C6-T8, as defined by the International Standards for Neurological Classification of Spinal Cord Injury.64 Incorporating level of injury over this broad range to capture the spectrum of autonomic dysfunction. Individuals with injuries below T8 will not be included to ensure transcutaneous spinal cord stimulation does not occur over the injury/glial scar, where it may have altered properties. The C6 level was chosen to ensure hand cold pressor stimuli triggers above level sympathetic activation. * Time since injury of greater than six months, given early changes in spinal cord connectivity and recovery prior to this. * Both individuals with and without currently implanted epidural spinal cord stimulators will be enrolled. * Twenty uninjured controls will also be enrolled. Exclusion criteria * History of clinically diagnosed cardiovascular disease, diabetes, autonomic neuropathies, neurological disorders (with exception of spinal cord injury for individuals in those cohorts), or are active smokers. * Individuals who are taking betablockers, antihypertensives, or other sympathetically active medications which they are unable to hold. * Women who are pregnant or lactating, given known hormonal influences on autonomic regulation.65,66 * Cognitive issues preventing informed consent for participation. * Body mass index \>30 kg/m2 for the uninjured controls only given increased risk of prediabetes and potential confounding normative values. * taking or being administered a medication known to potentially have adverse interactions with phenylephrine * in the judgement of the principal investigator, any illness or condition that will interfere with the patient's ability to comply with the protocol, compromise patient safety, or interfere with the interpretation of the study results
Contact & Investigator
Ryan J. Solinsky, MD
PRINCIPAL INVESTIGATOR
Mayo Clinic
Frequently Asked Questions
Who can join the NCT07210411 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 50 Years, studying Spinal Cord Injuries. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07210411 currently recruiting?
Yes, NCT07210411 is actively recruiting participants. Contact the research team at lund.erin@mayo.edu for enrollment information.
Where is the NCT07210411 trial being conducted?
This trial is being conducted at Rochester, United States.
Who is sponsoring the NCT07210411 clinical trial?
NCT07210411 is sponsored by Mayo Clinic. The principal investigator is Ryan J. Solinsky, MD at Mayo Clinic. The trial plans to enroll 80 participants.